Clopidogrel is a frequently used drug for prevention of blood clots after cardiac infarction or stent implantation. About 25-30% of the European population activates clopidogrel poorly (“slow metabolizers”). This results in limited efficacy of the drug and increases the risk for future infarctions. “Slow metabolizers” are particularly at risk if additional drugs are taken that inhibit metabolism of clopidogrel. Such drugs include antidepressants.
The gene test provided with this Box determines whether you metabolize clopidogrel sufficiently. In case of inefficient metabolism your physician can choose an alternative drug.